Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Post by ohbehaveon May 09, 2019 1:22pm
87 Views
Post# 29729871

Q4

Q4I believe investors need to look past Q1 numbers for PLX given capex was high on the new HZ well expenditures, differentials blew out "pre" pipeline restrictions and nat gas prices were weak ... it was an ugly quarter for most. It would have been nice to get the new well online in Q1 but realisitically operational delays happen and based on gas pricing alone Q1 should be much improved. In Q2 nat gas will soften but oil production from the new well should provide a material boost to PLX production and cash flow.

Its been a long drought and the junior sector has not had any love from investors for >4 years but the politics of Alberta have taken a turn for the better and following the SNC and Mark Norman scandals people in eastern Canada seem to be waking up so if you believe the polls there could also be a positive change at the Federal level that would be a huge lift for this beaten down sector come October. Meanwhile juniors are living out of their cash flow ... period and in the case of PLX, cash flow has been mostly gas which explains their paper acquisitions and cash dispositions (cash + cash flow) and they've also done a good job to date of managing their debt. The space is not for the faint of heart but considering that PLX has a focused use of proceeds in their now tested Rex play and multiple additional plays including an interesting Duvernay land position, it would seem that investors have excellent upside potential in PLX but it's just going to take some time to translate that into free cash flow and some patience is warranted. PLX should continue to be focused on the REX oil discovery and increased cash flow in the near to mid term and while that may require more patience than some are used to in the junior O&G sector any junior with an exiting new discovery, multiple additional core area development plays, a saleable land base in the Duverney and minimal debt should be what investors look for in any market ... no?   
<< Previous
Bullboard Posts
Next >>